Lilly partners with Entos to develop therapies for neurologic diseases
The collaboration will use Entos’ Fusogenix nucleic acid delivery technology and Lilly's therapeutic cargo to develop nucleic acid…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Jan 22
The collaboration will use Entos’ Fusogenix nucleic acid delivery technology and Lilly's therapeutic cargo to develop nucleic acid…
06 Jan 22
The shingles vaccine candidate will be developed based on BioNTech’s mRNA technology platform and Pfizer’s antigen technology
06 Jan 22
The partnership focuses on SRI's AI and automation platform, SynFini to advance the small-molecule drug discovery and development
05 Jan 22
The breakthrough therapy designation was granted based on data from LUMINOSITY, an ongoing Phase 2 study structured to…
05 Jan 22
Biogen has made an upfront payment of $60m to obtain a license for Ionis’ investigational antisense oligonucleotide (ASO)…
04 Jan 22
The FDA also expanded the EUA to include a third primary series dose for children aged five to…
04 Jan 22
The US FDA has recognised seven years of ODE for Xywav in June 2021 to treat cataplexy or…
03 Jan 22
The company has submitted the chemistry, manufacturing and controls (CMC) data module, completing final data packages required for…
03 Jan 22
The FDA approval was supported by positive results from Phase 3 SONICS and LOGICS studies evaluating Recorlev in…
30 Dec 21
Eplontersen is an investigational ligand-conjugated antisense (LICA) medicine, designed to treat all types of TTR amyloidosis (ATTR)